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 The decline of cognitive abilities with age is subject to much variability, and 
the factors that influence this are yet to be fully understood. This study aimed to 
explore the combined influence of physical activity (PA), and the BDNF gene on 
cognitive performance in older adults. Participants consisted of 140 female and 61 
male (N = 201), healthy older adults, aged 53 – 81 years (M = 64.2, SD = 6.63). 
BDNF genotype was ascertained via genetic testing, and participants were 
categorized as either Val carriers or Met carriers.  Participants were also grouped into 
high or low PA, as assessed with the self-report Incidental and Planned Exercise 
Questionnaire (IPEQ-WA). Cognitive performance was assessed via 
neuropsychological tests of executive functioning, short-term memory, long-term 
memory and learning. It was hypothesised that level of PA and BDNF genotype 
would have main effects on cognitive performance and that there would be an 
interaction between level of PA and BDNF genotype on cognitive outcome 
measures. However, contrary to our hypotheses, no significant main effects or 
interaction effects were observed between level of PA and the BDNF gene on any of 
the cognitive performance measures. These results suggest that, in a group of healthy 
older adults, level of PA and BDNF genotype are unrelated to cognitive 
performance.  
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A natural consequence of the human aging process is a decline in cognitive 
abilities (Salthouse, 2009). Behavioural research has identified clear patterns of 
reduction in various cognitive functions with age, particularly areas of memory and 
executive function (Hedden & Gabrieli, 2004). However, cognitive decline is subject 
to high levels of variability and many studies are now investigating what contributes 
to individual susceptibility, examining elements such as environmental and lifestyle 
influences or genetic factors (Erikson et al., 2008; Fratiglioni, Paillard-Borg & 
Winblad, 2004).  Physical Activity (PA) is a lifestyle factor linked to the 
maintenance and improvement of neurocognitive health (Stillman, Cohen, Lehman 
& Erikson, 2016). Higher levels of physical activity (activities in day-to-day life that 
involve moving the body and engaging the muscles) are associated with reduced risk 
of chronic diseases and more efficient cognitive function (Bherer, Erikson & Liu-
Ambrose, 2013). There is compelling research that supports PA as a moderator of 
cognitive decline, however individual differences are still evident (Bherer et al., 
2013).  The genetic and neurobiological components that underpin this process may 
provide further understanding. 
The BDNF gene controls the secretion and distribution of brain-derived 
neurotrophic factor (BDNF). BDNF is a neurotrophin found in the brain that plays a 
pivotal role in neural circuit development and growth, synapse formation and 
plasticity as well as memory and higher cognitive functions (Park & Poo, 2013). 
Recent genetic studies have identified a polymorphism in the human BDNF gene, 
known as Val66Met, which results in different versions of the gene that produce 
different responses in the regulation of BDNF (Park & Poo, 2013). Furthermore, 
genetic association studies have demonstrated that Val66Met plays a role in the 
variability of cognitive performance with aging (Miyajima, 2008). 
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Research has begun to examine how environmental influences, such as PA, 
can impact genetic predispositions, like BDNF Val66Met, in cognitive outcomes. 
Neurobiological studies have demonstrated that PA increases levels of neurotrophins 
particularly BDNF (Knaepen, Goekint, Heyman & Meeusen, 2010). Recently, 
studies have begun to examine the interaction between the BDNF Val66Met 
polymorphism and engagement in PA and their effect on cognitive performance in 
the domains of working memory, episodic memory and executive function (Canivet 
et al, 2015; Erikson et al., 2013; Thibeau, McFall, Anstey, Wiebe & Dixon, 2016). 
The present study seeks to expand the understanding of how the BDNF gene 
interacts with the association between PA and cognitive performance in an older 
population. 
Physical Activity and Cognitive Functioning 
 The relationship been PA and cognitive performance has been demonstrated 
in multiple domains of experimental research. In a meta-analysis of 15 observational 
studies investigating the association between PA and cognitive function in older 
adults, Sofi et a., (2010) found a significantly reduced risk of cognitive decline for 
participants engaged in PA. Across the 15 studies 33,816 non-demented subjects 
(Mean ages > 55) were observed over a 1–12 year period, and assessments of PA 
were obtained through self-report or questionnaires and cognitive performance was 
examined predominately through the mini-mental state exam (MMSE). The authors 
found that even modest levels of PA can have beneficial effects on cognition with the 
meta-analysis revealing a 38% reduced risk of cognitive decline for participants with 
a high level of PA compared to sedentary participants and, similarly, a 35% for 
participants performing low to moderate levels of PA (Sofi et a., 2010). 
  Clinical intervention research has also extensively assessed the association 
		
4	
between level of PA and cognitive outcomes. One meta-analysis looked at eighteen 
intervention studies examining the effect of fitness training on the cognitive 
performance of healthy but sedentary older adults (Colcombe et al., 2003). They 
found that, compared to controls, exercisers showed significantly improved results of 
moderate effect size in the cognitive domains of executive function, cognitive 
control, visuospatial processing and a significant increase of small effect for reaction 
time (Colcombe et al., 2003). In another review of epidemiological studies that 
examined modifiable factors associated with cognitive decline and dementia, 24 
studies linking PA to cognitive outcomes were assessed and of these 21 (87.5%) 
found a positive relationship between PA and cognitive performance (Beydoun, 
Beydoun, Gamaldo, Teel, Zonderman and Wang, 2014). Additionally, this review 
conducted a meta-analysis on 31 studies examining Alzheimer’s disease (AD) and 
found decreased PA to be a strong predictor of the disease, with lower vs higher 
levels of PA having a population attributable risk of 31.9% (Beydoun et al., 2014).  
 Animal studies have also demonstrated the benefits of PA on cognitive 
function, such as; better long-term and short-term memory in rats exposed to a 
swimming regime compared to non-exercised controls (Radak et al., 2001); 
improved object recognition memory for rats assigned to a rodent treadmill, running 
condition compared to rats in sedentary condition (Bechara & Kelly, 2013); and 
female cynomolgus monkeys, taught to run on treadmills for an hour a day, were 
significantly faster at learning the Wisconsin General Test Apparatus (WGTA; 
designed to test learning in primates) than controls (Rhyu et al., 2010). In addition, 
animal studies have enabled the research, through more invasive procedures than are 
possible with human subjects, to reveal the cellular and molecular mechanisms that 
occur with increased PA that impact the neurological structure of cognition (Kramer 
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and Erikson, 2007).  
The BDNF Val66Met Polymorphism: General Characteristics and Function 
 BDNF is one of a small number of secreted proteins that have been identified 
as regulating neural circuit development and function that continues across the 
lifespan (Poo, 2001). BDNF is initially produced as a precursor, proBDNF and then 
converted to mature BDNF intracellularly, both versions playing different cellular 
functions (Yoshida, Ishikawa, Iyo & Hashimoto, 2012). The cellular actions of 
BDNF occur through binding with one of its two receptors, mature BDNF binds to 
the high affinity receptor TrkB and proBDNF binds to the low-affinity receptor 
p75NTR, which often show opposing consequences (Reichardt, 2006). For example, 
the mature BDNF TrkB receptor facilitates neural survival and hippocampal long-
term potentiation (LTP; activity-dependent strengthening of neurons in the 
hippocampus) while the proBDNF p75NTR receptor, facilitates apoptosis (cell 
death) and hippocampal long-term depression (LTD; activity-dependent reduction in 
efficacy of neurons) (Reichardt, 2006; Woo, 2005; Zakharenko, 2003).  These 
cellular functions suggest that while mature BDNF plays a role in promoting 
memory and learning through stronger neural pathways, proBDNF weakens these 
connections. 
 BDNF is produced by the BDNF gene which is located at chromosome 11, an 
individual’s genetic instructions come from the matched pairs of chromosomes from 
their parents and as such there are two versions of a gene (Freberg, 2015). 
Alternative versions of a particular gene are known as alleles and the different alleles 
for the BDNF gene are valine (Val) and methione (Met). This variation in the BDNF 
gene is called a single nucleotide polymorphism (SNP) which results from an amino 
acid substitution (valine to methione) at codon 66, known as the BDNF Val66Met 
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polymorphism (Val66Met) (Egan et al., 2003). The genotype for a given individual 
reflects the alleles they carry and for BDNF they can occur as Val/Val genotype 
(known as Val homozygous), Val/Met genotype (known as Val/Met heterozygous) 
or Met/Met genotypes (known as Met homozygous). Generally, research refers to 
these genotypes as two groups Val carriers (the Val homozygotes) and Met carriers 
(both Val/Met and Met/Met genotypes) (Egan et al., 2003). The frequencies of these 
genotypes vary across populations with Asian populations showing the largest 
percentage of Met carriers (approx. 44%), European/caucasian populations showing 
a smaller frequency (approx. 20-25%) and African populations have very few Met 
carriers (approx.0.05%) (Petryshen et al., 2010).              
Cellular biology studies have demonstrated how Val66Met impacts the 
intracellular distribution and activity-dependent secretion of BDNF in neuronal cells 
(Chen et al., 2004).  The presence of the Met allele has been shown to lead to a 
decrease in the quantity of mature BDNF released. For Met carriers the structure of 
proBDNF (the initially released precursor form of BDNF) is altered which affects the 
conversion to mature BDNF and its ability to bind to its receptor TrkB which, as 
discussed previously, is the process associated with neurogenesis and hippocampal 
LTP (Brown et al., 2014; Chen et al., 2004; Reichardt, 2006). The less efficient 
BDNF trafficking may explain the neurocognitive deficits observed in Met carriers, 
however, these deficits have proven to be inconsistent particularly in the cognitive 
performance of an aging population. 
The BDNF Val66MetPolymorphism and Cognitive Performance 
The BDNF Val66Met polymorphism has been implicated in the variation 
seen in cognitive performance, with Val carriers and Met carriers demonstrating 
different cognitive outcomes. A neurocognitive physiological study from Egan et al. 
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(2003) examined the role of Val66Met in hippocampal based synaptic plasticity, 
learning and memory in a sample of 641 participants (M = 35 years). They assessed 
hippocampal function through; a cognitive assessment of memory (the Wechsler 
Memory Scale); neuroimaging to assess the activation of the hippocampus during a 
memory task; and an intracellular neurochemical measure that assessed hippocampal 
neuronal integrity and synaptic abundance. Egan and colleagues found lower scores 
in episodic memory, abnormal patterns of activation in the hippocampus and an 
impairment in the regulated secretion of BDNF for Met carriers. Miyajima et al. 
(2008) conducted an observational study examining the impact of Val66Met on the 
cognitive performance of 722 elderly participants and found Met carriers 
demonstrated lower scores compared to Val carriers on measures of delayed 
memory, processing speed and general intelligence.  
It has been demonstrated that the effects of Val66Met may become more 
apparent with age. Li et al. (2009) examined the age-dependent effect of the genetic 
variant on episodic memory in two studies, one of 382 younger (M = 25 years) and 
another of 566 older (M = 66 years), healthy participants. They found no significant 
difference in memory performance in the younger groups between Val and Met 
genotypes. However, in the older groups, Met carriers recalled significantly less than 
Val carriers, suggesting the magnitude of the genetic effect may be impacted by the 
cognitive decline of aging.  A longitudinal study from Ghisetta et al. (2014) assessed 
Val66Met and the processing speed of 376 older participants (M = 83.9 years) over a 
13-year period with the Digit-Letter (DL) task. This study also demonstrated an 
effect of aging in that, while scores at the first assessment did not differ significantly 
across genotype, Met carriers showed a significantly greater decline in processing 
speed than Val carriers across six assessments over the 13 years.  
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 An opposite pattern of association has also been demonstrated, with Met 
carriers demonstrating greater performances compared to Val carriers in some 
cognitive domains, particular those related to executive function. In a study 
examining task switching, Gajewski, Hengstler, Golka, Falkenstein and Beste (2011) 
assessed 131 healthy older adults (M = 70.5 years) on speed and variability of 
reaction time (RT) and error rates. The Val carriers were observed to be generally 
slower, had greater reaction time variability and higher error rates than Met carriers 
(Gajewski et al., 2011). The same team of Gajewski, Hengstler, Golka, Falkenstein 
and Beste (2012) conducted another study examining Val66Met and the Stroop 
paradigm (a measure of RT when there is interference in identifying a stimuli) in the 
same cohort of 131 participants. They found that Met carriers performed better than 
Val carriers, suggesting a greater ability for interference control in elderly Met 
carriers.  
A meta-analysis conducted by Mandelman and Grigorenko (2012) examined 
studies that looked at the relationship between Val66Met and cognitive outcomes. 
Across 31 independent samples, comprising of 7095 subjects, the meta-analysis did 
not establish any significant relationships between Val66Met genotype and measures 
of general cognitive ability, memory, executive functioning, visual or cognitive 
fluency (Mandelman & Grigorenko, 2012). Additionally, a recent study, of 360 
subjects between the ages of 50-79 years, found no difference in episodic memory 
performance between Val carriers and Met carriers (Stuart, Summers, Valenzuela & 
Vickers, 2014). 
The Role of BDNF in the Effect of PA on Cognitive Outcomes 
 Both human and rodent studies have provided strong evidence that the 
positive effects of PA on the brain and cognition are facilitated by increased levels of 
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BDNF, neurogenesis and cell proliferation in the hippocampus (an area of the brain 
known to play a fundamental role in declarative and spatial memory and the decline 
of cognitive function with aging) (Kramer and Erikson, 2007; Pinel, 2014).  
One early animal study revealed significant, strong, positive associations 
between the level of PA and the level of BDNF expression in the hippocampal 
regions of rats (Oliff, Berchtold, Isackson & Cotman, 1998). Another study 
examined whether BDNF mediated the enhanced learning, demonstrated by 
exercised rats, by chemically blocking BDNF expression in the hippocampus during 
exercise (Vaynman, Ying & Gomez-Pinilla, 2004). Vaynman et al. (2004) found that 
the blocking BDNF reduced the learning and recall abilities to the same level as the 
sedentary control group, additionally, they found that higher levels of learning and 
recall were correlated with higher levels of BDNF expression. A more recent rodent 
study examined age-related memory decline and the associated decrease in 
neurogenesis (promoted by mature BDNF) and increase in apoptosis (promoted by 
proBDNF) in the hippocampus (Kim et al., 2011). They compared young and old rats 
and found that exercise improved short term and spatial memory in older rats. Post-
mortem tissue examinations confirmed significant increases in mature BDNF after 
exercise for both young and old rats and an increase in neurogenesis and reduction in 
apoptosis for the older exercised rats compared to older sedentary rats (Kim et al., 
2011). Increased expression of BDNF following PA has also been found in the 
striatum of rats, an area of the brain known to play a role in learning through reward 
and reinforcement and in executive functions such as inhibition of control (Marais, 
Stein & Daniels, 2009). 
 Neuroimaging studies of the human brain have revealed an association 
between BDNF and age-related decline in the size of the hippocampus (Erikson et 
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al., 2010). In non-demented older adults, the hippocampus has been demonstrated to 
shrink by as much as 1-2% a year and is one possible mechanism for the normal 
experience of cognitive decline with aging (Raz et al., 2005). Erikson et al. (2010) 
conducted MRIs on 142 older adults, without dementia, measured blood serum levels 
of BDNF and assessed spatial memory. They found smaller hippocampal volume, 
lower levels of serum BDNF and poorer memory performance were associated with 
increasing age and, after controlling for age, found that lower levels of serum BDNF 
were associated with poorer memory and smaller hippocampal size (Erikson et al., 
2010). An invention study however, found that an increase in physical activity was 
associated with increases in serum levels of BDNF, increased hippocampal volume 
and improved memory (Erikson et al., 2011). Erikson and colleagues conducted a 
randomized controlled trial examining the effect of exercise training on 120 older 
adults, with an aerobic exercise group (N = 60) and a stretching control group (N = 
60). They found that over a one year period, exercise had increased the size of the 
hippocampus by 2% (counteracting the natural reduction seen with aging) which was 
associated with increased serum levels of BDNF and improvements in spatial 
memory (Erikson et al., 2011).  
 This research demonstrates a clear association between BDNF, exercise and 
cognitive performance in aging, however an important element to consider in the role 
of endogenous BDNF is how it is produced. The fact that the BDNF Val66Met 
polymorphism has been shown to impact the neurotrophin’s distribution and cellular 
functions leads to the question of how an individual’s genotype would interact with 
the effect of PA on age-related cognitive outcomes (Chen et al., 2004).  
Interaction between the BDNF Val66Met Polymorphism and Physical Activity  
Research has demonstrated that BDNF is associated with both cognitive 
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functioning and PA however, only four studies were found that have examined the 
interaction between the BDNF Val66Met polymorphism, PA and the decline of 
cognitive performance with aging. These studies have been conducted using varying 
methods and have resulted in conflicting evidence. 
 One study from Canivet and colleagues (2015) examined the interaction 
between Val66Met and PA using a single measure of episodic memory (the Delayed 
Score of the Logical Memory II subtest of the Wechsler Memory Scale), with 205 
participants aged 55 and older. To assess PA, they used two questionnaires (the 
NASA/JSC PA Scale and the Historical Leisure Activity Questionnaire) to categorise 
participants as active or inactive based on their METs h/week (a unit for describing 
energy expenditure). They found that Val carriers demonstrated a significant 
interaction with levels of PA on episodic memory performance with active Val 
carriers recalling more items than both active and inactive Met carriers (Canivet et 
al., 2015). Another study from Thibeau and colleagues (2016) of 577 participants (M 
= 70 years), assessed the same gene and environment interaction with executive 
function. They found that higher levels of everyday physical activity in Val carriers 
showed a significant association with better executive function performance that was 
not seen for Met carriers (Thibeau et al., 2016). Both studies concluded that while 
PA enhances cognitive performance, it is not enough to counteract the deleterious 
effects for Met carriers and its influence is more beneficial for Val carriers (Canivet 
et al., 2015; Thibeau et al., 2016). 
In contrast, a study from Kim et al. (2011) examined the interaction between 
BDNF genotypes and PA with cognitive decline and dementia diagnosis using the 
mini mental state exam (MMSE) in an elderly population (65 and older). PA was 
measured using a self-rated 4-point scale, ranging from very active to not at all 
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active, on questions relating to work and leisure activities. Over a two-year period, 
they found greater physical activity was associated with less cognitive decline and a 
decreased number of dementia cases diagnosed across genotypes, however this 
relationship only reached statistical significance for Met carriers. These results 
suggest that increased levels of physical activity have significantly more positive 
effect on cognitive health for Met carriers than Val carriers (Kim et al., 2011).   
In addition, a study by Erikson et al. (2013) examined the moderation of 
Val66Met on the effect of PA with a number of cognitive assessments but in a 
middle-aged population (M = 44.59 years). PA was assessed using a self-report 
questionnaire about daily living, work and leisure activities, indexing frequency and 
duration which results in an estimate of weekly kilocalories expended. They found 
significant positive associations between levels of PA and the cognitive factors of 
working memory, episodic memory, switching tasks and visuo-spatial memory but 
only working memory resulted in a significant interaction effect for Val66Met. Met 
carriers demonstrated significantly poorer performance in working memory than Val 
carriers at the lower end of PA but the difference disappeared with greater levels of 
PA (Erikson et al., 2013). The authors of these two studies conclude that, as a result 
of increasing BDNF levels from greater PA, Met carriers benefit more robustly from 
exercise than Val carriers, offsetting the genetic vulnerability (Erikson et al., 2013; 
Kim et al., 2011). 
The methodological differences of the preceding four interaction studies 
outlined make comparing the evidence challenging. Two of these studies have 
examined the interaction between PA and BDNF Val66Met with only one aspect of 
cognitive functioning and each in a different domain (episodic memory or executive 
function) (Canivet et al., 2015; Thibeau et al., 2016). The third study assesses the 
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interaction with pathological ageing as assessed by the MMSE (Kim et al., 2011). 
The MMSE has a number of limitations in regards to accurate diagnosis of dementia 
and cognitive impairment and it is suggested as a tool more reliable at ruling out 
cognitive decline that definitively diagnosing it (Ismael, Rajii & Shulman, 2010). 
The fourth study uses a neuropsychological test battery but examined a middle-age 
population (Erikson et al., 2013). In addition, all four studies use different methods 
to assess PA although all are self-reported questionnaires.  
Rationale, Aims and Hypotheses 
The conflicting evidence demonstrates the complexity of the variation seen in 
cognitive performance with aging and as such it is unlikely that only one factor 
alone, such as PA or genotype, explain its trajectory. Therefore, it is necessary for 
research to focus on the interaction between genes and environmental factors to 
further understand the etiology of cognitive aging. The proposed study will examine 
level of PA and BNDF Val66Met with a battery neuropsychological tests, assessing 
the domains of executive functioning, short-term memory and long-term memory 
and learning, in a healthy population of 50 years and older to further investigate their 
relationship with cognitive function. 
The aim of this observational study is to examine the interaction of two 
factors that have both been demonstrated to impact cognitive performance, one 
environmental factor, level of PA, and one genetic factor, the BDNF Val66Met 
polymorphism. This study proposes that the more efficient trafficking and regulation 
of BDNF for the Val carriers, in combination with the increase production of BDNF 
from PA will result in significantly better scores across cognitive measures for active 
Val carriers, as compared to Met carriers.  
1. We hypothesise that as age-related cognitive decline has been demonstrated to be 
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mitigated by increased levels of PA, there will be a main effect of PA on 
cognitive performance whereby participants with higher levels of PA, compared 
to participants with low levels of PA, will demonstrate significantly better 
performances across the cognitive measures of executive function, working 
memory and long-term memory.  
2. It is also hypothesised that due to the more efficient trafficking and regulation of 
BDNF for Val carriers over Met carriers, there will be a significant effect of the 
BDNF Val66Met polymorphism on cognitive outcomes, whereby Met carriers 
will demonstrate significantly poorer cognitive performances in measures of 
executive function, working memory and long-term memory.  
3. We predict that the cognitive boost from PA will not be enough to counter the 
deleterious effect for the Met carriers, and therefore there will be a significant 
interaction between level of PA and BDNF genotype.  Specifically, it is predicted 
that Val carriers demonstrating high levels of PA will perform significantly better 
than Met carriers with high levels of PA, and Val carriers who reported low 
levels of PA will score significantly higher than Met carriers who reported low 
levels of PA, on measures of executive function, working memory and long-term 
memory. 
Method 
Participants 
 Participants were recruited from a larger sample who had consented to take 
part in the Tasmanian Healthy Brain Project (THBP; Ethics HREC #H11070) 
(Summers, Saunders, Valenzuela, Summers, Ritchie, Robinson & Vickers, 2013). 
The THBP is a prospective longitudinal study examining whether late-life education 
effects age-related cognitive decline and risk of dementia. Participants were initially 
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screened by the THBP and excluded if they had any history of conditions associated 
with cognitive impairment (such as dementia, multiple sclerosis, traumatic brain 
injury or current psychiatric diagnosis (Summers et al., 2013). Dementia was 
assessed using the Mattis Dementia Rating Scale and anyone scoring below the 
recommended cut-off of 133 was excluded (Mattis, 1988). The THBP volunteers 
were notified of the upcoming ancillary study through a regular newsletter they 
receive as part of the project and asked to participate in this separate study on the 
relationship between physical activity, genotype and cognitive function. 
Participants for the present study consisted of 61 male and 140 female 
community-residing healthy older adults. The total number of 201 participants were 
aged between 53 – 81 years, with a total mean age of 64.2 years (SD = 6.63).  
Materials 
The following tests were used as to assess depression, anxiety and general 
intellectual capacity. Both anxiety and depression have been demonstrated to 
negatively impact cognitive performance in older persons (Bierman, Comijs, Jonker 
& Beekman, 2005). An individual’s base level of general intellectual functioning is 
also a factor that will influence performance in cognitive assessments (Mathias, 
Bowden & Barrett-Woodbridge, 2007).  
Hospital Anxiety Depression Scale (HADS). The HADS is a measure of 
anxiety and depression in both patients and the general population (Zigmond & 
Snaith, 1983).  It contains 14 items, seven questions for anxiety and seven questions 
for depression, with higher scores representing greater levels of symptom severity. It 
is considered a valid and reliable measure of the symptoms of anxiety and depression 
(Bjelland, Dahl, Haug & Neckelmann, 2002).  
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Wechsler Test of Adult Reading (WTAR). TheWTAR provides a stable and 
reliable estimate of intellectual capacity (Wechsler, 2001). Participants are required 
to read and pronounce 50 words with atypical grapheme to phoneme translation 
which assesses their ability to apply rules of pronunciation with previous learning. 
Raw score is then converted to a standardised score of estimated full-scale IQ.  The 
WTAR has been shown to have robust accuracy as a measure of verbal general 
intellectual skill (Whitney, Shepard, Mariner, Mossbarger and Herman, 2010). 
Cognitive Test Battery. A standardized battery of neuropsychological tests 
was administered by the THBP and all participants completed cognitive assessments 
annually. The full THBP cognitive assessment took approximately four hours to 
complete and participants were encouraged to take short breaks as needed to avoid 
fatigue (Summers, et al., 2013). The results of the following assessments were used 
in this study as a measure of performance in executive functioning, short-
term/working memory, long-term memory and learning.  
Executive Functioning  
 The Trail Making Test (TMT). The TMT is a two-part task. In Part A, the 
subject has to sequentially connect 25 numbered circles, presented randomly on a 
sheet of paper, without lifting their pencil from the page. Part B requires the subject 
to do the same but alternate between sequencing random circles with letters or 
numbers across the page i.e. connecting from 1 to A to 2 to B etc.  For this study, 
Part B was used, as it is considered a reliable and valid measure of executive control 
abilities. This is scored as the time (in seconds) it takes participants to complete the 
task, with a better performance being reflected by a shorter time recorded. A higher 
performance in the TMT B is an indicator of good executive control abilities, 
primarily task-switching ability (Sanchez-Cubillo et al., 2009).  
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 The Stroop Test (24 item Victoria version). The Stroop Test (24 item 
Victoria version) is a brief version of the Stroop task which examines response 
inhibition. It contains 24 items on 3 tasks, the first two of which require participants 
to name the colour of dots and neutral words printed in different colours and scores 
are the total time in seconds it takes to complete the task. The third is an interference 
task where the words are actually names of colours printed in contrasting colours, i.e. 
name the colour of the word ‘blue’ printed in red ink. Scores for the interference task 
are total time in seconds taken to complete it divided by the time it took to complete 
the dot task.  Performance in this task has been demonstrated to negatively correlate 
with age and it is considered a psychometrically strong measure of response 
inhibition in an elderly population (Troyer, Leach & Strauss, 2006).  
 Controlled Oral Word Association Test (COWAT). The COWAT examines 
executive function by assessing verbal fluency. This is measured by asking 
participants to name as many words as possible beginning with the same specified 
letter but excluding proper nouns such as names of people or places. There are three 
trials, lasting one minute each for three different letters (e.g. F, A, S). The score is 
the total number of correct words recorded across three trials. It is considered a valid 
and reliable clinical instrument for neuropsychological assessment (Ruff, Light, 
Parker & Levin, 1996).  
Short-term Memory   
  The Digit Span Test (DSP). The DSP is a sub-test of the Wechsler Adult 
Intelligence Scale (WAIS-IV) used for assessing working memory (Wechsler, 1997). 
The DSP assesses short-term memory span for auditory-verbal information by asking 
participants to repeat back numbers in correct order and the longest list correctly 
recalled is recorded. It is a valid and reliable measure of short-term memory.
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 The Letter-Number Sequencing Test (LNS). The LNS is a sub-test of the 
Wechsler Adult Intelligence Scale (WAIS-IV) used for assessing working memory 
(Wechsler, 1997). The LNS assesses the capacity to manipulate verbally presented 
information in short-term memory by asking the participant to repeat a sequence of 
randomly presented letters and numbers but in ascending order for the numbers and 
alphabetically for the letters. The score is the longest list of items correctly recalled. 
Long-term Memory and Learning 
 Rey Auditory Verbal Learning Test (RAVLT). The RAVLT is a measure of ability 
to encode, consolidate, store and recall verbal memory. The examiner reads out-loud 
a series of 15 unrelated words and the participant is required to repeat as many as 
possible back to the examiner. A series of 5 trials is conducted, and the total of words 
correctly recalled is recorded for each trial.  RAVLT total performance score is 
represented by adding the results of all five trials. This has been demonstrated to be a 
valid and reliable measure of episodic declarative memory (de Sousa, Malloy-Diniz 
& Hamdan, 2012). Additionally, verbal learning can be assessed by comparing the 
scores across the five trials of the RAVLT.  
 Rey Complex Figure Test (RCFT). The Rey Complex Figure Test (RCFT) – 
evaluates visuospatial ability and visual memory by asking subjects to reproduce a 
complicated line drawing, first by copying and then by delayed recall. It is scored 
according to the presence of a detail and the location of a detail. The recall trial has 
been found to be a reliable and valid measure of learning and memory for complex 
visual information in an elderly population (Berry, Allen & Schmitt, 1991).  
 Physical Activity Level. 
Incidental and Planned Exercise Questionnaire (IPEQ-WA) The IPEQ is 
specifically designed for use in an elderly population and delineates different types 
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of physical activities common for this age-group, such as housework, gardening, 
walking, or a scheduled exercise session (Delbaere, Hauer & Lord, 2010).  In the 
IPEQ-WA, respondents estimate their usual weekly PA over the past three months, 
which has been demonstrated to show greater reliability by allowing for the week-to-
week variability in activity which is more likely to occur in an older cohort 
(Delbaere, Hauer & Lord, 2010).  The IPEQ-WA consists of ten questions, with 
answers on a six-point Likert scale, asking about particular activities over the past 3 
months, average times participated in per week and the average number of minutes 
engaged in the activity (Doma, Speyer, Leicht & Cordier, 2017).  In order to 
establish standardized levels of PA, the individual scores of the IPEQ-WA activities 
were summed and then converted into a number known as a MET Value, which is an 
estimated energy cost of human physical activity. The various activities were 
classified in terms of MET values by using the MET Values Compendium of 
Physical Activities, which is a widely-accepted tool for use in clinical and research 
settings to categorise levels of physical activity (Ainsworth et al., 2011). The total 
number of minutes exercised per week is then able to be converted to a total number 
of MET minutes per week. The IPEQ-WA has been evaluated as a valid and reliable 
measure of PA in later-age cohorts with good criterion validity established against 
objective measures, such as accelerometers (Merom et al., 2014). 
 Genetic Testing. DNA was collected via saliva sample by THBP using the 
Oragene DNA self-collection kits (DNA Genotek Inc., 2012). BDNF genotype has 
been established by the THBP following the method described by Sheikha, Hayden, 
Kryski, Smith and Singha (2011).  All DNA samples were analysed twice to confirm 
genotype. 
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Procedure 
After approval from the Tasmanian Human Research Ethics Committee 
(HREC) (H0016623 see Appendix A) the volunteer participants of the THBP were 
contacted, via their already established preferred mode of communication, by either 
email or mail out. A participant information sheet was included, along with a consent 
form for completion if they chose to proceed with the current study (see Appendix 
B). To ensure maintenance of confidentiality, all communication with participants 
and handling of their identifiable data was conducted solely by the authorized project 
manager from THBP, Dr Kimberley Stuart (who was also a member of this PA study 
team). After completion of the consent form participants were then asked to 
complete the IPEQ-WA survey, either through an online link to SurveyMonkey 
attached to their email or by filling out the paper questionnaire. Upon receipt of the 
completed consent form and IPEQ-WA, the THBP team allocated each participant an 
alphanumeric code, and extracted the cognitive and genetic information from the 
THBP, which was then released to the current study. 
Statistical Analysis and Data Screening 
Participants were categorized into genotype groups based on their BDNF 
alleles. Participants were designated as either Val carriers, if they possessed only Val 
alleles (Val/Val homozygotes) or Met carriers if they possessed one or two Met 
alleles (Val/Met heterozygotes or Met/Met homozygotes).  It is recommended that a 
range of 500 to 1000 MET minutes per week at minimum is necessary to experience 
the health benefits of PA (United States Department of Health and Human Services, 
2008).  As such, the present study categorised participants with MET minutes of 
1000 or greater as being in the high PA group and participants with MET minutes of 
less than 1000 as being in the Low PA group.  
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SPSS version 24 was used to conduct all analyses. Chi-square and t-tests 
were used to compare both the genotype groups and the level of PA groups on 
demographic factors. Pearson correlations were used to examine the relationship 
between age and each of the cognitive performance measures, which revealed 
significant relationships between age and five of our seven cognitive performance 
measures, Table 1). As a result, ANCOVAs were performed with age as a covariate 
in the analysis of the cognitive performance measures. 
 Table 1. 
 Correlations Between Age and Cognitive Performance Measures 
Cognitive Function Measure 
Correlation 
with Age (r) 
p value 
Executive Functioning TMT B .379 <.001 
 Stroop Interference .212 .002 
      COWAT -.088 .192 
Short-term Memory Digit Span -.098 .146 
  LNS -.268 <.001 
Long-term Memory 
and Learning 
RAVLT  
RCFT 
-.325 
-.317 
<.001 
<.001 
Note: Significance at a = .05 
 
The chi-square and t-tests revealed there were no significant differences 
between the demographic measures of age, sex, body mass index (BMI; an indicator 
of healthy weight in relation to height), HADS scores, WTAR score, years of 
education, months since cognitive assessment, THBP experimental group and BDNF 
genotypes, as displayed in Table 2. 
The t-tests revealed a significant difference between PA level and HADS 
scores, such that scores of anxiety were moderately higher for the low PA group than 
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the high PA group t (199) = 3.25, p = .001, d = .53 and scores of depression were 
also moderately higher for the low PA group than the high PA group t (199) = 3.75, 
p <.001, d = .61. No other significant differences between level of PA and 
demographic measures were observed, this analysis is presented in Appendix C.  
Table 2. 
 
Demographic Data and Analysis of Differences Between BDNF Val66Met Genotypes 
 Met Carrier 
(n = 77) 
Val Carrier 
(n = 124) 
t-test/χ2 p value 
 
Age (years) 
     Mean (SD) 
 
 
63.96 (6.79) 
 
 
64.35 (6.55) 
 
 
-.409 
 
 
.683 
Sex 
     Males  
     Females 
 
23 (29.9%) 
54 (70.1%) 
 
38 (30.6%) 
86 (69.4%) 
 
.013 
 
 
.908 
BMI 
     Mean (SD) 
 
27.21 (5.42) 
 
27.12 (11.33) 
 
.063 
 
.950 
HADS Scores 
     Anxiety Mean (SD) 
     Depression Mean (SD) 
 
4.23 (3.30) 
2.13 (2.23) 
 
4.71 (3.17) 
1.98 (2.3) 
 
-1.019 
.439 
 
.309 
.661 
WTAR FSIQ     
     Mean (SD) 112.71 (5.50) 112.64 (5.63) .095 .924 
Total Years of Education 16.51 (2.95) 16.20 (6.55) .661 .509 
Months since Cognitive 
Tests 
18.16 (7.03) 17.16 (7.46) .939 .349 
THBP Experimental Group 
     University Study  
     Controls 
 
65 (84.4%) 
12 (15.6%) 
 
94 (75.8%) 
30 (24.2%) 
 
2.13 
 
 
.144 
Level of PA 
     Low 
     High 
 
25 (32.5%) 
52 (67.5%) 
 
25 (20.2%) 
99 (79.8%) 
 
3.85 
 
 
.050 
Note: Significance at a = .05  
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A series of 2 (BDNF val carrier vs met carrier) X 2 (high PA vs low PA) 
between subjects ANCOVAS were conducted in order to compare performance 
between BDNF Val66Met genotype and level of PA on each of the seven cognitive 
tasks. The dependent variables (DV) were the seven cognitive assessment tasks; the 
TMT B, Stroop interference, COWAT, Digit Span, LNS, RCFT and RAVLT recall. 
A repeated measures ANCOVA was run to examine any differences between the two 
IV groups, BDNF genotype and level of PA, across the 5 RAVLT trials with age as a 
covariate. Significance was determined with an alpha level of .05. ANCOVAS were 
conducted using the HADS anxiety and depression measures as covariates revealing 
a significant effect of depression on performance in the TMT B, F (1,194) = 8.02, p 
=.005, a significant effect of depression on performance in the RAVLT total, F 
(1,195) = 5.29, p =.02 and a significant effect of anxiety on performance in the 
STROOP interference F (1,194) = 3.91, p = .049. Therefore, these measures are used 
as covariates in the final analysis.  
Results 
The BDNF allele frequencies were examined using the Hardy-Weinberg 
Equilibrium chi square and based on the estimated expected frequencies of a 
caucasian population, 75% Val Carriers and 25% Met Carriers (Petryshen et al., 
2010). The observed frequencies were Val/Val genotype (n =124, 62%), Val/Met 
genotype (n = 70, 35%) and Met/Met genotype (n = 7, 3%) which did not differ 
significantly from the Hardy-Weinberg equilibrium c2 (2, N=201) = 3.81, p = 0.149. 
The frequency for the two genotype groups used for analysis in this study were Val 
carrier (n = 124, 62%) and Met carrier (n = 77, 38%). 
Tests of normality and skewness indicated that scores on all the cognitive 
measures deviated from normal so logarithmic and square root transformations were 
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performed to investigate their effect on the data. However, as the transformations did 
not significantly alter results, and due to the robustness of ANOVA to violations of 
normality, the untransformed data was analysed (Field, 2013).  Windsorizing was 
used to convert extreme outliers to the nearest non-outlier score (Field, 2013).   
Means and standard deviations for all neuropsychological test results, 
excluding the RAVLT 1 to 5, are presented in Table 3. The mean scores of the 
RAVLT trials are presented in figure 1, where the learning curve for each of the IV 
groups is illustrated. 
 
Table 3. 
 Means and Standard Deviations for Neuropsychological Test Performance by 
BDNF Genotype and Level of Physical Activity. 
 Met Carrier Val Carrier 
 Low PA 
 n = 25 
High PA 
 n = 52 
Low PA 
 n = 25 
High PA 
 n = 99 
Executive Functioning     
     TMT Ba 60.91 (21.19) 54.55 (29.34) 50.60 (17.36)  55.73 (22.77) 
     Stroop Interference 1.81 (.30) 1.81 (.43) 1.81 (.36) 1.84 (.33) 
     COWAT 51.84 (8.67) 50.96 (11.75) 52.44 (9.97) 52.85 (11.09) 
Short-term Memory     
     Digit Span 18.72 (3.70) 19.37 (4.08) 19.20 (3.92) 18.57 (3.68) 
     LNS 11.68 (2.10) 11.88 (2.48) 11.96 (2.88) 11.77 (2.32) 
Long-term Memory 
and Learning 
    
     RAVLT  50.52 (7.09) 52.08 (10.23) 51.64 (10.70) 53.48 (9.26) 
     RCFT 27.86 (6.53) 29.22 (5.61) 29.20 (4.96) 28.69 (6.21) 
Note: a A lower score on this test indicates better performance. Figures in parentheses are standard 
deviations. 
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Figure 1. The mean scores for trials one to five of the RAVLT and the learning curve 
for each of the four independent variables; Met carrier with Low PA, Met carrier 
with High PA, Val carrier with Low PA and Val carrier with High PA.  
 
Main effects of BDNF Genotype and Physical Activity Level on Cognitive 
Performance 
 
	 The 2 Way ANCOVAs revealed no significant main effects of BDNF 
genotype (Val carrier or Met carrier) on any of the cognitive performance measures 
of executive functioning, short-term memory or long-term memory, indicating there 
are no differences in cognitive processing due to BDNF polymorphic variation. 
There was also no significant main effect of level of PA (Low PA or High PA) on 
performance in any cognitive domain, with no differences in functioning between PA 
groups on measures of executive functioning, short-term memory or long-term 
memory. Contrary to our hypotheses, there were no significant interactions between 
BDNF Val66Met genotype and level of PA on any measures of cognitive 
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performance. The repeated measures ANCOVA found no significant difference in 
performance across the 5 trials of the RAVLT between BDNF genotype F (4,693) = 
1.36, p =.25,  hp2 = .007 or level of PA F (4,693) = 2.43, p = .054, hp2 = .012 and no 
significant interaction F (4,693) = 1.154, p = .33, hp2 = .006, following Greenhouse-
Geisser adjustments due to violations of sphericity.  The ANOVA results are 
presented in Appendix D. 	
Discussion 
 The decline of cognitive abilities with age is subject to much variability and 
this study aimed to explain some of this variance through the combined influence of 
one environmental factor, level of PA, and one genetic factor, BDNF genotype. 
Contrary to our hypotheses, no significant main effects or interaction effects were 
observed between level of PA and the BDNF Val66Met polymorphism on any of the 
cognitive performance measures of executive function, short term memory or long-
term memory and learning.  
Our first hypothesis was that there would be a main effect of PA on cognitive 
outcomes, whereby participants with higher levels of PA would perform better than 
participants with low levels of PA. While the significant benefits of physical activity 
on cognitive performance have been demonstrated in research studies and clinical 
interventions (Colcombe et al., 2003; Sofi et a., 2010), we found no significant 
difference in scores between high levels of PA and low levels of PA in the cognitive 
performance measures of executive function, short-term memory, or long-term 
memory and learning, and therefore our first hypothesis was not supported. 
Our second hypothesis was that there would be a main effect of the BDNF 
Val66Met polymorphism on cognitive performance, whereby Met carriers 
(participants with the at-risk allele) would achieve lower scores in the cognitive 
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measures than Val carriers. Although previous research has shown that the BDNF 
Val66Met polymorphism is associated with significant differences in cognitive 
outcomes between genotypes (Egan et al., 2003; Ghisetta et al., 2014; Miyajima et 
al., 2008), we found cognitive performance did not vary between BDNF genotypes, 
Val carriers and Met carriers, across all the measures of executive function, short-
term memory or long-term memory and learning. This is consistent with the results 
of Mandelman and Girgorenko (2012) and Stuart et al., (2014) who also found no 
evidence of significant relationships between cognitive performance and the BDNF 
Val66Met polymorphism. Therefore, our second hypothesis was not confirmed, but 
aligns with some previous research, as will be considered further below. 
Our third hypothesis was that there would be a significant interaction 
between BDNF genotype and level of PA, with Val carriers in the High PA group 
outperforming Met carriers in the High PA group and Val carriers in the Low PA 
group outperforming Met carriers in the Low PA group in measures of cognitive 
performance. This is the first study to be conducted examining the interactive effect 
between level of PA and the BDNF Val66Met polymorphism on cognitive function 
in an older adult population using a battery of neuropsychological tests, and as such 
cannot be directly compared against previous findings. However, there was no 
evidence of any interactions and therefore these results suggest that, in a group of 
healthy older adults, level of PA and BDNF genotype do not interact in a manner 
which significantly influences cognitive performance in older adults. 
 The findings of our study partially align with those from Erickson et al. 
(2013) who found no significant interaction between BDNF and PA on measures of 
episodic memory, visuo-spatial memory or task-switching in a longitudinal study of 
a middle-age population (Mean Age = 44.59 years). However, conflicting with our 
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results, they did find a significant interaction effect on four assessments of working 
memory in that higher levels of PA resulted in improved performance for Met 
carriers only, suggesting that for working memory Met carriers benefit more from 
PA than Val carriers. Our results also conflict with those of Kim et al. (2011), who 
found that higher levels of PA were significantly more beneficial for Met carriers, 
who showed less cognitive decline than Val carriers with increased activity, in a 
population of 732 community elders (Mean Age = 71.2 years). Their results showed 
significantly better scores on the MMSE as PA levels increased for participants 
possessing the Met allele. 
It is important to consider how the previous evidence reflects the actual 
behavioural outcomes for participants and whether the differences are enough to 
indicate a meaningful difference in cognitive performance. Erickson and colleagues 
(2013) had a sample size of over 1000 participants and the effects sizes they 
observed were very small. Three of their working memory measures reported effect 
sizes partial r 2 that were less than .01 and the fourth had an effect size of partial r2 = 
.019. In a guide for meaningful effect sizes in clinical terms, Ferguson suggests that 
for clinical relevance, partial r2 of at least .04 is needed, which suggests that whilst 
significant, Erickson et al’s findings may not be substantive enough to indicate 
practical importance. Additionally, Kim et al. (2011) reported odds ratios which 
ranged from 1.50 – 1.60 for cognitive decline in each of their logistic regression 
models for which Ferguson (2009) advises at least 2.0 to be meaningful. As 
cognitive decline was measured by a reduced score in the MMSE from baseline to 
the follow-up assessment the odds ratios suggests that while scores were 
significantly different they may not be practically meaningful. 
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The meaningful difference in performance can also be questioned in the study 
from Canivet and colleagues (2015). Their findings demonstrated the opposite 
pattern of results in that, in a population of 205 older adults (Mean Age = 72.7 years) 
Val carriers benefit more from increased PA than Met carriers do. They reported 
active Val carriers performed significantly better in a measure of episodic memory 
than inactive Val carriers, with a small effect size of partial eta squared .03 and no 
significant effect of PA on Met carriers. Similar results for Val carriers were found 
by Thibeau et al. (2016), where increased levels of PA were significantly associated 
with higher scores in executive functioning which was not seen in for Met carriers. 
In a population of 577 (Mean Age = 70.5 years), the authors found that for each unit 
increase in physical activity for Val carriers there was a significant increase of .43 in 
their scores of executive function, while Met carriers did not show a significant 
improvement with each increase in activity affecting their scores by .13 units. This 
result does indicate that more active Val carriers may experience a meaningful 
improvement in their executive functioning. The functions that represent the 
mechanisms of cognitive performance, such as executive functioning, have been 
demonstrated to decline over the adult lifespan (Hedden & Gabrieli, 2001). In 
contrast to the previous three studies, Thibeau and colleagues (2016), conducted a 
longitudinal study over a nine-year period, which may have produced the more 
robust findings. 
The results of our study, that found no main effects or interaction effects 
between BDNF Val66Met and PA on cognitive performance across a battery of 
neuropsychological tests, contradict the previous findings of the same gene and 
environment interaction study. However, three of these studies revealed significant 
performances but with small effect sizes, bringing into question the true meaningful 
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effect of the interaction on cognitive performance demonstrated (Canivet et al., 2015; 
Erickson et al., 2013 & Kim et al., 2011). The fourth study, from Thibeau et al. 
(2016) demonstrated a significant, moderate positive effect of PA on cognitive 
performance for Val carriers over time but methodological differences make it 
difficult to compare the results of this interaction study with ours. Their population 
was older, with a mean age of 70.5 years and assessed decline over time while the 
age of our participants younger with a mean age of 64.2 years and assessed only one 
performance. It is possible that while there is no difference in the cognitive 
performance between genotypes and PA activity in our population, a significant 
variation in performance may occur in an older population. 
Limitations 
 The younger mean age of the participants in our study may prove to be a 
limitation as it might have been too young to see the differences in performance 
between the BDNF Val66Met genotypes. Our findings confirmed the negative 
association between age and cognitive performance with three of the measures 
having a significant negetive correlation with participant age, however, sharper 
declines are observed over the age of 70 years (Hedden & Gabrieli, 2001). Levels of 
BDNF have also been shown to be negatively associated with age and the decline has 
been demonstrated to continue to occur at a significant level in older adults from 70 
up to 103 years old (Zeigenhorn et al., 2007). This evidence, in combination with the 
association of the MET allele with lower availability of BDNF in the brain and lower 
brain volume, suggests it is possible that the negative impact for MET carriers on 
cognition won’t be seen until much later in the life-span (Brown et al., 2014).  
The IPEQ-WA, used for this study, has been shown to have good 
psychometric properties and internal consistency with the averaging of three-months 
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activities allowing for the week-to-week variability of more elderly participants 
(Doma, Speyer, Leicht & Cordier, 2017). However, use of self-report to determine 
PA level does have limitations. Participant’s self-reports are a subjective measure 
that can result in a bias where they overinflate their estimates of activity frequency 
and duration (Shepherd, 2003). However, a systematic review and meta-analysis of 
24 studies examining the relationship between physical activity and cognitive 
decline, across both questionnaire and objective measures, found 21 of the studies 
confirmed the positive association (Beydoun et al., 2014). This demonstrates that 
these varying measures are sensitive enough to establish the level of activity required 
to impact cognitive functioning. In addition, one of the particular benefits for self-
report questionnaires in an aging population is the assessment of PA over various 
domains, such as gardening and housework, rather than the more rigid, objective 
measures that don’t measure incidental activities (Warren et al., 2009). It is possible 
however that the use of an objective measure of physical activity, such as an 
accelerometer, might produce more robust effects and interactions with the BDNF 
Val66Met polymorphism than those observed in this study.  
Another limitation may be volunteer/participation bias which is systematic 
error due to differences between those who chose to participate in studies and those 
who do not. Participation bias has been examined in a study of 1000 older adults by 
comparing those who volunteered to participate in an exercise study and those who 
did not (de Souto Barreto, Ferrandez & Salina-Serre, 2013). The researchers found 
that participants who were willing to take part in an exercise study were younger, 
had less physical function decline and higher levels of PA in comparison to those 
who declined to participate. Our demographic data revealed a breakdown of 25% (n 
= 50) in the Low PA group and 75% (n = 151) in the High PA group possibly 
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reflecting a bias in our population towards more physically active people. The effect 
of unequal sample sizes is a reduction in the power of the analysis to be able to 
detect a significant difference between the groups (Field, 2013). It is therefore 
reasonable to conclude that an increase in the number of less active participants 
would result in a more powerful study more able to detect a significant effect. 
Implementing stratified sampling to ensure a more equal representation between PA 
groups would address this. 
Sample size is a considerable concern for studies examining the field of 
single nucleotide polymorphisms (SNP) such as BDNF Val66Met. In order to predict 
power, an estimate of effect size is used which is guided by the evidence in the 
literature and, as outlined previously the evidence for this gene x environment 
interaction study is minimal and inconsistent, making estimating effect sizes 
challenging. In a review of genetic research Payton (2006) suggests that replication 
for studies of SNPs with cognitive associations require around 1000 participants to 
achieve 80% power and our sample size of 201 participants may have lacked the 
power to observe a significant interaction between the groups. In fact, in a review of 
candidate gene x environment (CG x E) interaction research, Duncan & Kelly (2011) 
found that only 27% of replication attempts found significant effects and that a 
publication bias existed where predominately novel, significant CG x E studies are 
reported. The authors conclude that this bias reporting results in the literature 
reflecting a more robust pattern of effects than actually exist in CG x E studies and 
suggest that the majority of the significant findings represent Type I errors. In 
conjunction with this information, it is possible the small effect sizes reported in the 
studies above are an indication of Type I errors and there was not a true significant 
difference between the groups cognitive performances. 
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Future Research 
 Due to the mixed findings to date, there is no discernable pattern of evidence 
yet, that can clearly define the relationship between the BDNF Val66Met 
polymorphism, level of PA and cognitive outcomes. It is possible that the variation 
in studies is due to interactions with other unexplored variables that future research 
should examine. 
Although the interaction studies have exhibited conflicting results, the BDNF 
Val66Met polymorphism has become a very consistent candidate gene in cognition 
research (Mandelman & Grigorenko, 2012). In a review of candidate gene x 
environment interaction research, Dick and colleagues (2015) suggest that in order to 
account for a greater amount of the variance in the dependent variables it will be 
necessary for future research to examine genetic haplotypes. A haplotype is a 
combination of alleles or set of SNPs that tend to be inherited together (Jacobsson et 
al., 2008). There are very few studies that have examined the potential collusive 
effect on cognition of a haplotype including BDNF that could explain why the results 
of single genetic association studies have been so inconsistent. 
As has been demonstrated with the BDNF Met allele, the APOE e4 allele is 
associated with reduced cognitive function in an aging population with inconsistent 
results (Papenberg, Lindenberger & Bäckman, 2015). In one study, Ward et al. 
(2014), examined the combined influence of genetic polymorphisms, BDNF 
Val66Met and apolipoprotein E (APOE) on episodic memory function. Ward and 
colleagues (2014) found that while there was no significant difference for the 
independent genotypes on cognitive performance, there was a significant gene-gene 
interaction on episodic memory and the combination of the two risk alleles, the 
BDNF Met allele and the APOE e4, resulted in the lowest mean performance. 
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Similarly, another research project examined the synergistic associations of BDNF, 
APOE and the genetic polymorphism of an additional gene implicated in healthy 
cognitive aging, catechol-O-methyltransferase (COMT) (Sapkota, Vergote, 
Westaway & Jhamandas, 2015). Sapkota and colleagues (2015) demonstrated an 
additive effect, whereby the combination of all three genetic risk alleles resulted in 
significantly reduced executive functioning performance that was not observed in the 
alternative combinations. It is therefore plausible that is may be the combination of 
genes, operating in an additive or synergistic way, that account for more of the 
variability demonstrated in cognitive performance with aging.  
In addition, BDNF is not the only gene that had been associated with the 
effects of physical activity on cognitive outcomes. The interaction study discussed 
previously from Thibeau and colleagues (2016) also investigated the variation in the 
IDE (insulin degrading enzyme) gene and found a relationship between IDE, 
physical activity and executive functioning. Their results showed that carriers of the 
IDE G allele (considered to be the protective allele) that participated in higher levels 
of PA had significantly higher scores and less decline over time than the less active 
IDE G carriers. Increased amounts of physical activity in later life have also been 
demonstrated to mitigate the cognitive deficits associated with the APOE e4 allele 
(Luck et al., 2014). Also, in a study from Liang et al. (2010), the genetic 
susceptibility of increased amyloid deposition (a biomarker for Alzheimer’s disease) 
in APOE e4 carriers was demonstrated to be reduced in participants who were more 
physically active. It is therefore evident that the variability seen in the cognitive 
benefits demonstrated by increased PA could be the result of multiple genetic 
influences. 
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As well as the inclusion of further genetic variables, cognitive performance 
can be modified by lifestyle factors in addition to PA. It is possible that an effect 
may be found when examining the relationship between the BDNF Val66Met 
polymorphism, cognitive function and other influential and interacting health factors. 
For example, dietary influences have been demonstrated to impact cognitive function 
with aging with a review from Parrott and Greenwood (2007) concluding that there 
is evidence that maximizing consumption of plant matter and healthy oils while 
limited saturated fats positively influences age-related cognitive changes. Taken 
together, all of this evidence suggests that future studies seeking to investigate the 
variability of cognitive decline associated with aging should focus on examining 
environment variables and their interactions with the synergistic effects of genetic 
haplotypes. 
Finally, future studies need to employ different methodologies in order to 
assess the effect of the BDNF Val66Met polymorphism and level of PA on the 
decline associated with cognitive aging. Previous research has demonstrated the 
negative impact of the Met allele on cognitive performance in an older adult 
population over a number of years (Saptoka et al., 2017; Thibeau et al., 2016). These 
results imply that it is possible the negative effect of the Met allele confers its 
cognitive disadvantage over time and in order to find a significant difference 
between groups a longitudinal study would be more appropriate. Additionally, 
implementing a randomized controlled trial approach with an exercise intervention 
would enable a causal link to be drawn between the interaction of PA and BDNF 
genotype on cognitive outcomes if a significant effect is found. 
 
 
		
36	
Conclusion 
 This research study sought to examine the interactive effects of the BDNF 
Val66Met polymorphism and level of PA on cognitive performance in a healthy 
older adult population. While previous evidence has demonstrated the role of both 
BDNF genotype and PA independently and interactively in cognitive outcomes, our 
findings found no significant differences between the groups in measures of 
executive functioning, short-term memory, long-term memory or learning. The 
results of this study conclude that the BDNF Val66Met polymorphism and PA have 
no effect on the cognitive performance of healthy older adults. Limitations included 
our subjective self-report measure of PA, uneven distribution of Low PA and High 
PA participants and the age of our population. Future studies should consider using 
randomized controlled trials with objective measures of activity and take into 
account that it is possible that the effect on cognitive performance might not be 
evident until after the age of 70 years when the decline associated with normal 
cognitive aging occurs more rapidly. Additionally, examining genome wide genetic 
associations and the additive and synergistic relationships of haplotypes are also 
important considerations in the future of research into the variability of normal age-
related cognitive decline.	
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Appendix C. 
Demographic Data and Analysis of Differences between Levels of Physical Activity 
(PA) 
 Low PA 
(n = 50) 
High PA 
(n = 151) 
t-test/χ2 p value 
 
Age (years) 
     Mean (SD) 
 
64.28 (6.64) 
 
64.18 (6.65) 
 
.093 
 
.926 
Sex 
     Males  
     Females 
 
14 (28.0%) 
36 (72.0%) 
 
47 (31.1%) 
104 (68.9%) 
 
.174 
 
 
.677 
BMI 
     Mean (SD) 
 
28.77 (6.06) 
 
 26.63 (10.31) 
 
1.377 
 
.170 
HADS Scores 
     Anxiety Mean (SD) 
     Depression Mean (SD) 
 
5.78 (3.62) 
3.06 (2.56) 
 
4.11 (2.97) 
1.70 (2.09) 
 
3.250 
3.75 
 
.001 
<.001 
WTAR FSIQ     
     Mean (SD) 112.76 (6.05) 112.64 (5.42) .136 .892 
Total Years of Education 15.58 (3.23) 16.56 (3.13) -1.910 .058 
Months since Cognitive Tests 17.84 (7.44) 17.44 (7.28) .332 .740 
THBP Experimental Group 
     University Study  
     Controls 
 
44 (88.0%) 
6 (3.0%) 
 
115 (76.2%) 
36 (23.8%) 
 
3.186 
 
 
.074 
BDNF Genotype 
      Met Carrier 
      Val Carrier 
 
25 (50.0%) 
25 (50.0%) 
 
52 (34.4%) 
99 (65.6%) 
 
3.85 
 
.050 
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Appendix D.  
Analysis of Covariance (ANCOVA) Between Genotype and Physical Activity Level 
on Cognitive Performance Measures with Age as a Covariate 
 df F p Cohen’s d 
Executive Functioning     
TMT Ba           Genotype 1,194 1.40 .24 .07 
PA Level 1,194 0.56 .46 .001 
Interaction 1,194 1.42 .24 .009 
Stroopb        Genotype 1,194 0.05 .83 .09 
PA Level 1,194 0.60 .44 .04 
Interaction 1,194 0.001 .97 .04 
COWAT      Genotype 1,196 0.50 .48 .14 
PA Level  1,196	 0.02 .89 .006 
Interaction 1,196	 0.13 .72 .02 
Short-term Memory     
Digit Span   Genotype 1,197	 0.05 .83 .12 
PA Level 1,197	 0.00 .99 .03 
Interaction 1,197	 1.01 .32 .02 
LNS             Genotype 1,196	 0.10 .75 .004 
PA Level 1,196	 0.001 .97 .004 
Interaction 1,196	 0.24 .63 .004 
Long-term Memory                   
      and Learning 
   
RAVLTa      Genotype 1,195 0.84 .36 .16 
PA Level 1,195	 0.37 .55 .20 
Interaction 1,195	 0.09 .76 .02 
RCFT            Genotype 1,196 0.29 .59 .003 
PA Level 1,196	 0.16 .69 .05 
Interaction 1,196	 0.93 .34 .002 
Note: Significance at a = .05.  a = HADS depression score was included as a covariate in the 
analysis.   b = HADS anxiety score was included as a covariate in the analysis.  
